BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, Liang S. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Pharmacol Res 2021;170:105732. [PMID: 34139345 DOI: 10.1016/j.phrs.2021.105732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Yang C, Huang XM, Lv PP, Yang YK, Zhao JN, Zhao SY, Sun WJ. Knockdown of FBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1α. Front Oncol 2021;11:796839. [PMID: 34869045 DOI: 10.3389/fonc.2021.796839] [Reference Citation Analysis]
2 Kang X, Huo Y, Jia S, He F, Li H, Zhou Q, Chang N, Liu D, Li R, Hu Y, Zhang P, Xu A. Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma. Front Oncol 2022;12:939605. [DOI: 10.3389/fonc.2022.939605] [Reference Citation Analysis]
3 Shen LJ, Sun HW, Chai YY, Jiang QY, Zhang J, Li WM, Xin SJ. The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. Front Oncol 2021;11:804412. [PMID: 34976842 DOI: 10.3389/fonc.2021.804412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gudkov A, Shirokorad V, Kashintsev K, Sokov D, Nikitin D, Anisenko A, Borisov N, Sekacheva M, Gaifullin N, Garazha A, Suntsova M, Koroleva E, Buzdin A, Sorokin M. Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer. Front Mol Biosci 2022;9:753318. [DOI: 10.3389/fmolb.2022.753318] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q, Hou J. A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma. Front Oncol 2021;11:783194. [PMID: 34869036 DOI: 10.3389/fonc.2021.783194] [Reference Citation Analysis]
6 Li H, Liu J, Fan N, Wang H, Thomas AM, Yan Q, Li S, Qin H. Nav1.6 promotes the progression of human follicular thyroid carcinoma cells via JAK-STAT signaling pathway. Pathol Res Pract 2022;236:153984. [PMID: 35753135 DOI: 10.1016/j.prp.2022.153984] [Reference Citation Analysis]
7 Liu W, Ren D, Xiong W, Jin X, Zhu L. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02253-0] [Reference Citation Analysis]
8 Wang JH, Zeng Z, Sun J, Chen Y, Gao X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol Res 2021;173:105869. [PMID: 34481973 DOI: 10.1016/j.phrs.2021.105869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 He X, Sun H, Jiang Q, Chai Y, Li X, Wang Z, Zhu B, You S, Li B, Hao J, Xin S. Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front Oncol 2021;11:735447. [PMID: 34381736 DOI: 10.3389/fonc.2021.735447] [Reference Citation Analysis]
10 Mao D, Xu M, Jiang Q, Sun H, Sun F, Yang R, Chai Y, Li X, Li B, Li Y. A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. Front Pharmacol 2022;13:951831. [DOI: 10.3389/fphar.2022.951831] [Reference Citation Analysis]
11 Luo M, Sun H, Jiang Q, Chai Y, Li C, Yang B, Hong Z. Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma. Front Oncol 2021;11:777356. [PMID: 34926286 DOI: 10.3389/fonc.2021.777356] [Reference Citation Analysis]
12 Du F, Sun H, Sun F, Yang S, Tan H, Li X, Chai Y, Jiang Q, Han D. Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Front Pharmacol 2022;13:924523. [DOI: 10.3389/fphar.2022.924523] [Reference Citation Analysis]
13 Wang J, Liu R, Zhao Y, Ma Z, Sang Z, Wen Z, Yang X, Xie H. Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. Front Oncol 2021;11:743055. [PMID: 34513717 DOI: 10.3389/fonc.2021.743055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]